UroGen Pharma (LTS:0XOD) Cyclically Adjusted Book per Share: $3.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0XOD UroGen Pharma Ltd LTS:0XOD
52 GF Score
Price $38.60
GF Value $22.63
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Cyclically Adjusted Book per Share?

UroGen Pharma LTS:0XOD -5.55% 52 Cyclically Adjusted Book per Share is $3.17 as of Mar. 2026. GuruFocus rates LTS:0XOD with a GF Score™ of 52/100 and a GF Value™ of $22.63 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

UroGen Pharma's adjusted book value per share for the three months ended in Mar. 2026 was $-2.551. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.17 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-03), UroGen Pharma's current stock price is $38.60. UroGen Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $3.17. UroGen Pharma's Cyclically Adjusted PB Ratio of today is 12.18.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of UroGen Pharma was 13.09. The lowest was 5.37. And the median was 7.20.


UroGen Pharma  (LTS:0XOD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

UroGen Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=38.60/3.17
=12.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of UroGen Pharma was 13.09. The lowest was 5.37. And the median was 7.20.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


UroGen Pharma Cyclically Adjusted Book per Share Related Terms


UroGen Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Cyclically Adjusted Book per Share Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.13

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 3.13 3.17

LTS:0XOD vs PVLA, AUPH, RAPP: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, UroGen Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Cyclically Adjusted PB Ratio falls into.


LTS:0XOD
52GF Score
UroGen Pharma Ltd LTS:0XOD
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, UroGen Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.551/330.2130*330.2130
=-2.551

Current CPI (Mar. 2026) = 330.2130.

UroGen Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 1.487 241.432 2.034
201703 0.000 243.801 0.000
201706 5.693 244.955 7.674
201709 5.787 246.819 7.742
201712 4.983 246.524 6.675
201803 8.005 249.554 10.592
201806 7.163 251.989 9.387
201809 6.433 252.439 8.415
201812 5.556 251.233 7.303
201903 11.542 254.202 14.993
201906 10.781 256.143 13.899
201909 10.070 256.759 12.951
201912 8.575 256.974 11.019
202003 7.093 258.115 9.074
202006 6.484 257.797 8.305
202009 5.461 260.280 6.928
202012 4.347 260.474 5.511
202103 3.433 264.877 4.280
202106 2.517 271.696 3.059
202109 1.408 274.310 1.695
202112 0.375 278.802 0.444
202203 -0.753 287.504 -0.865
202206 -1.800 296.311 -2.006
202209 -2.750 296.808 -3.060
202212 -3.863 296.797 -4.298
202303 -4.972 301.836 -5.439
202306 -5.891 305.109 -6.376
202309 -1.361 307.789 -1.460
202312 -2.007 306.746 -2.161
202403 -1.111 312.332 -1.175
202406 0.736 314.175 0.774
202409 0.605 315.301 0.634
202412 -0.208 315.605 -0.218
202503 -1.008 319.799 -1.041
202506 -2.021 322.561 -2.069
202509 -2.467 324.800 -2.508
202512 -2.181 324.054 -2.222
202603 -2.551 330.213 -2.551

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $3.17 mean?
UroGen Pharma (LTS:0XOD) has a Cyclically Adjusted Book per Share of $3.17 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's Cyclically Adjusted Book per Share too high?
UroGen Pharma's current Cyclically Adjusted Book per Share is $3.17. Overall, UroGen Pharma has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Cyclically Adjusted Book per Share compare to PVLA and AUPH?
UroGen Pharma's Cyclically Adjusted Book per Share of $3.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Cyclically Adjusted Book per Share is $3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.63, compared to a current price of $38.60 — trading 70.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is $3.17. UroGen Pharma's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Cyclically Adjusted Book per Share is $3.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of $38.60 is trading 70.6% above its estimated GF Value™ of $22.63. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0XOD:

  • Cyclically Adjusted Book per Share: $3.17
  • GF Value™: $22.63 vs. price of $38.60 (70.6% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UroGen Pharma Business Description

Other Exchanges URGN:USAUR8:Germany
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
52GF Score

Get the complete analysis for LTS:0XOD

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.60
Price
$22.63
GF Value